These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36736339)

  • 1. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    van Linschoten RCA; Jansen FM; Pauwels RWM; Smits LJT; Atsma F; Kievit W; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; van der Woude CJ; Hoentjen F;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):343-355. PubMed ID: 36736339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study.
    Smits LJT; Pauwels RWM; Kievit W; de Jong DJ; de Vries AC; Hoentjen F; van der Woude CJ;
    BMJ Open; 2020 May; 10(5):e035326. PubMed ID: 32461297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
    van Linschoten RCA; Jansen FM; Pauwels RWM; Smits LJT; Atsma F; Kievit W; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; van der Woude CJ; Hoentjen F;
    Dig Dis Sci; 2024 Jun; 69(6):2165-2174. PubMed ID: 38594435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
    Schulberg JD; Wright EK; Holt BA; Hamilton AL; Sutherland TR; Ross AL; Vogrin S; Miller AM; Connell WC; Lust M; Ding NS; Moore GT; Bell SJ; Shelton E; Christensen B; De Cruz P; Rong YJ; Kamm MA
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):318-331. PubMed ID: 34890567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Noor NM; Lee JC; Bond S; Dowling F; Brezina B; Patel KV; Ahmad T; Banim PJ; Berrill JW; Cooney R; De La Revilla Negro J; de Silva S; Din S; Durai D; Gordon JN; Irving PM; Johnson M; Kent AJ; Kok KB; Moran GW; Mowat C; Patel P; Probert CS; Raine T; Saich R; Seward A; Sharpstone D; Smith MA; Subramanian S; Upponi SS; Wiles A; Williams HRT; van den Brink GR; Vermeire S; Jairath V; D'Haens GR; McKinney EF; Lyons PA; Lindsay JO; Kennedy NA; Smith KGC; Parkes M;
    Lancet Gastroenterol Hepatol; 2024 May; 9(5):415-427. PubMed ID: 38402895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
    Jansen FM; van Linschoten RCA; Kievit W; Smits LJT; Pauwels RWM; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; Hoentjen F; van der Woude CJ;
    J Crohns Colitis; 2023 Nov; 17(11):1771-1780. PubMed ID: 37310877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
    Yanai H; Levine A; Hirsch A; Boneh RS; Kopylov U; Eran HB; Cohen NA; Ron Y; Goren I; Leibovitzh H; Wardi J; Zittan E; Ziv-Baran T; Abramas L; Fliss-Isakov N; Raykhel B; Gik TP; Dotan I; Maharshak N
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):49-59. PubMed ID: 34739863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
    Ponsioen CY; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Bossuyt PMM; Hart A; Warusavitarne J; Buskens CJ; van Bodegraven AA; Brink MA; Consten ECJ; van Wagensveld BA; Rijk MCM; Crolla RMPH; Noomen CG; Houdijk APJ; Mallant RC; Boom M; Marsman WA; Stockmann HB; Mol B; de Groof AJ; Stokkers PC; D'Haens GR; Bemelman WA;
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):785-792. PubMed ID: 28838644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
    Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
    BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
    Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
    Khanna R; Bressler B; Levesque BG; Zou G; Stitt LW; Greenberg GR; Panaccione R; Bitton A; Paré P; Vermeire S; D'Haens G; MacIntosh D; Sandborn WJ; Donner A; Vandervoort MK; Morris JC; Feagan BG;
    Lancet; 2015 Nov; 386(10006):1825-34. PubMed ID: 26342731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
    Sands BE; Irving PM; Hoops T; Izanec JL; Gao LL; Gasink C; Greenspan A; Allez M; Danese S; Hanauer SB; Jairath V; Kuehbacher T; Lewis JD; Loftus EV; Mihaly E; Panaccione R; Scherl E; Shchukina OB; Sandborn WJ;
    Lancet; 2022 Jun; 399(10342):2200-2211. PubMed ID: 35691323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.